thalidomide has been researched along with Hidradenitis Suppurativa in 12 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hidradenitis Suppurativa: A chronic suppurative and cicatricial disease of the apocrine glands occurring chiefly in the axillae in women and in the groin and anal regions in men. It is characterized by poral occlusion with secondary bacterial infection, evolving into abscesses which eventually rupture. As the disease becomes chronic, ulcers appear, sinus tracts enlarge, fistulas develop, and fibrosis and scarring become evident.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS)." | 9.30 | Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. ( Davelaar, N; Mus, AMC; Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019) |
| "We report the "real-life" use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition." | 9.05 | Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature. ( De Simone, C; Garcovich, S; Giovanardi, G; Malvaso, D; Peris, K, 2020) |
| "Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited." | 6.90 | Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. ( Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019) |
| "Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS)." | 5.30 | Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers. ( Davelaar, N; Mus, AMC; Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019) |
| "We report the "real-life" use of apremilast in the treatment of multimorbid patients with hidradenitis suppurativa and review its potential role in the management of this severe condition." | 5.05 | Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature. ( De Simone, C; Garcovich, S; Giovanardi, G; Malvaso, D; Peris, K, 2020) |
| "Effective anti-inflammatory treatments for hidradenitis suppurativa (HS) are limited." | 2.90 | Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. ( Prens, EP; van der Zee, HH; van Doorn, MBA; Vossen, ARJV, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Agud-Dios, M | 1 |
| Arroyo-Andrés, J | 1 |
| Rubio-Muñiz, C | 1 |
| Postigo-Lorente, C | 1 |
| Lanna, C | 1 |
| Mazzilli, S | 1 |
| Zangrilli, A | 1 |
| Bianchi, L | 1 |
| Campione, E | 1 |
| Garcovich, S | 1 |
| Giovanardi, G | 1 |
| Malvaso, D | 1 |
| De Simone, C | 1 |
| Peris, K | 1 |
| Proietti, I | 1 |
| Michelini, S | 1 |
| Mambrin, A | 1 |
| Di Fraia, M | 1 |
| Tolino, E | 1 |
| Balduzzi, V | 1 |
| Bernardini, N | 1 |
| Marchesiello, A | 1 |
| Porta, N | 1 |
| Skroza, N | 1 |
| Romeo, G | 1 |
| Di Cristofano, C | 1 |
| Petrozza, V | 1 |
| Potenza, C | 1 |
| Aarts, P | 2 |
| Vossen, ARJV | 4 |
| van der Zee, HH | 4 |
| Prens, EP | 4 |
| van Straalen, KR | 2 |
| Dudink, K | 1 |
| Ardon, CB | 1 |
| Weber, P | 1 |
| Seyed Jafari, SM | 1 |
| Yawalkar, N | 1 |
| Hunger, RE | 1 |
| Davelaar, N | 1 |
| Mus, AMC | 1 |
| van Doorn, MBA | 2 |
| Kerdel, FR | 1 |
| Azevedo, FA | 1 |
| Kerdel Don, C | 1 |
| Don, FA | 1 |
| Fabbrocini, G | 1 |
| Kerdel, FA | 1 |
| Hotz, C | 1 |
| Sbidian, E | 1 |
| Ingen-Housz-Oro, S | 1 |
| Chosidow, O | 1 |
| Wolkenstein, P | 1 |
| Reddick, CL | 1 |
| Singh, MN | 1 |
| Chalmers, RJ | 1 |
2 reviews available for thalidomide and Hidradenitis Suppurativa
| Article | Year |
|---|---|
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Hidradenitis Suppurativa; Human | 2020 |
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
Topics: Adalimumab; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Biological Products; CD40 Anti | 2021 |
3 trials available for thalidomide and Hidradenitis Suppurativa
| Article | Year |
|---|---|
Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, T-Lymphocyt | 2019 |
Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Hidradenitis Suppurativ | 2019 |
Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Gastrointestinal Diseases; Hidradenitis Supp | 2019 |
7 other studies available for thalidomide and Hidradenitis Suppurativa
| Article | Year |
|---|---|
Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast.
Topics: Antibodies, Monoclonal, Humanized; Crohn Disease; Hidradenitis Suppurativa; Humans; Thalidomide | 2022 |
One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Resistance, Multiple; Hidradenitis Suppurativa; Humans | 2019 |
A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis and SAMPUS.
Topics: Hidradenitis Suppurativa; Humans; Psoriasis; Thalidomide | 2020 |
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Duration of Therapy; Female; Follow-Up Studies; Hidr | 2021 |
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Dr | 2017 |
Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option.
Topics: Adolescent; Adult; Female; Hidradenitis Suppurativa; Humans; Immunosuppressive Agents; Male; Remissi | 2019 |
Successful treatment of superficial pyoderma gangrenosum associated with hidradenitis suppurativa with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Com | 2010 |